Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double Blinded, Randomized, Priorix®- and Placebo-controlled, Trial to Evaluate the Optimal Dose of MV-CHIK Vaccine (Against Chikungunya Virus) in Regard to Immunogenicity, Safety and Tolerability in Healthy Volunteers

NCT02861586 is registered in ClinicalTrials.gov with Themis Bioscience GmbH as lead sponsor.

NCT NCT02861586
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02861586 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double Blinded, Randomized, Priorix®- and Placebo-controlled, Trial to Evaluate the Optimal Dose of MV-CHIK Vaccine (Against Chikungunya Virus) in Regard to Immunogenicity, Safety and Tolerability in Healthy Volunteers
Lead sponsor
Themis Bioscience GmbH
Phase
Phase 2
Overall status
Completed
Start date
August 17, 2016
Completion date
April 16, 2018
Enrollment
263 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

chikungunya virus infection